undamentalytics Newsletter
Sign in

Hyperfine, Inc. income statement

In fiscal 2025, Hyperfine, Inc. reported revenue of $13.6m, up 5.2% on the year before, operating income of −$37.1m (a -273.4% margin) and net income of −$35.6m, or −$0.43 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue01711131417
Cost of revenue1366778
Gross profit−0−115679
Research and development15262822221716
Selling and marketing310141091010
General and administrative6273220171616
Operating income−23−65−74−48−43−37−34
Income before tax−23−65−73−44−41−36−35
Income tax—000000
Net income−23−65−44−44−41−36−35
Diluted EPS−$0.77−$0.88−$1.04−$0.62−$0.56−$0.43−$0.38
Diluted shares (average)30m74m70m71m72m82m93m
EBITDA−23−64−73−47−42−36−32

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HYPR vs SRTSHYPR vs MDAIHYPR vs ZJYL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Hyperfine, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Hyperfine, Inc.